Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01353547 · ClinicalTrials.gov registry record

Genes and Environment in Multiple Sclerosis

A clinical trial of Multiple Sclerosis, sponsored by Columbia University.

Recruiting
Registry status
5,000
Enrollment target
5
Study locations

NCT01353547: Recruiting study of Multiple Sclerosis, sponsored by Columbia University.

NCT01353547 is a study of Multiple Sclerosis that is actively recruiting participants, run by Columbia University. The registered enrollment target is 5,000 participants, above the 569-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (779% higher). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01353547, a study of Multiple Sclerosis, is actively recruiting participants, sponsored by Columbia University.

RECRUITING
Registry status
5,000 participants
Enrollment target
5
Study locations

Study Summary

The purpose of the research study is to identify the genetic, environmental and immune profiles that may increase a person's risk of developing multiple sclerosis (MS). While MS is not a disease caused by a single variation in genetic material (DNA), a single environmental factor, or a single malfunction in immune cells, there are genetic alterations, environmental exposures and immunologic factors that make the development of MS more likely. Obtaining information about who is at risk for MS will be beneficial in the future if the investigators can identify effective ways to prevent or slow down the progression of this disease.

Primary Outcome

For each subject, weighted integrated risk score will be calculated, combining genetic burden and environmental exposure. A distribution of the risk score will be generated for the cohort. At this stage, the study will assess whether there is an increase in subjects with a diagnosis of MS (validated by a letter or copy of clinical records from the subject's neurologist) within the higher end vs. the lower end of the risk score distribution.

Conditions Studied

Study Locations (5)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Brigham and Women's Hospital - Boston

Maryland

  • National Institute of Neurological Disorders and Stroke - Bethesda

New York

  • Columbia University Irving Center - New York

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 5,000 participants
Start Date 2017-10-01
Est. Completion 2040-10
Columbia University

958 total trials

What NCT01353547 shows while recruiting

NCT01353547 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 569-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (779% higher).

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT01353547 lists 5 locations in 4 states (Massachusetts, Maryland, New York).

Frequently Asked Questions

What is clinical trial NCT01353547 about?

NCT01353547 is a clinical study titled "Genes and Environment in Multiple Sclerosis". The purpose of the research study is to identify the genetic, environmental and immune profiles that may increase a person's risk of developing multiple sclerosis (MS). While MS is not a disease caused by a single variation in genetic material (DNA), a single environmental factor, or a single malfun...

What is the current status of trial NCT01353547?

This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2017-10-01. Estimated completion is 2040-10.

What conditions does trial NCT01353547 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

Who is sponsoring clinical trial NCT01353547?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01353547 being conducted?

This trial has 5 study locations across Maryland, Massachusetts, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01353547's enrollment target sits among peer trials

5,000 6th of 315 higher than 309 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00060541 · 5,000 participants

    Evaluation and Treatment of Neurosurgical Disorders

  • NCT00575081 · 5,000 participants

    Physiological Brain Atlas Development

  • NCT00736749 · 5,000 participants

    Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

  • NCT00900198 · 5,000 participants

    Collection of Tissue Samples for Cancer Research

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01353547, the US trial registry maintained by the National Library of Medicine. NCT01353547 (large enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.